HPTN **HIV Prevention** Trials Network

BACKGROUND

The ambitious 95-95-95 strategy was announced by UNAIDS in 2014, aiming to end the AIDS epidemic by 2030 by achieving 95% diagnosed among all people living with HIV (PLHIV), 95% on antiretroviral therapy (ART) among diagnosed, and 95% virally suppressed (VS) among treated. An intermediate goal of 90-90-90 was set for 2020. These targets have been adopted by many countries implying that treatment should be prioritized in resource allocation.

MODELING OBJECTIVES

We explore the importance of the **heterogeneity in ART and VS coverage** among different PLHIV groups by sexual risk behavior for the expected reduction in HIV incidence if the UNAIDS targets are met in South Africa by 2030.

RISK EQUATION MODEL

- A risk equation model was used to simulate annual HIV incidence by tracking the transmission from PLHIV assuming that **30% of them are engaged in high-risk behavior** with more frequent sexual activity (100 vs.40 sex acts annually);
- **The model** was parameterized with the 2015 South African HIV prevalence and 85-58-76 treatment cascade (i.e. 37% viral suppression of PLHIV)¹, and calibrated to 2015 HIV incidence among the adult population 15-49 years²;
- Condom use was not explicitly modeled but accounted for in the estimated HIV transmission risk per act during calibration;
- Estimated transmissions from each PLHIV are calculated as one minus the probability to avoid transmission in multiple exposures when the PLHIV is has a given ART and VS status;
- HIV prevention is implemented as reduction in per-act risk for assumed proportion (coverage) of partners of high-risk PLHIV.

Model parameters	Value
Proportion of high-risk PLHIV	30%
HIV prevalence in 2015	17%
HIV prevalence in 2030	10%, 17%
Annual number of partners of high-risk PLHIV	5
Annual number of partners of low-risk PLHIV	1
Number of acts per partner (high-risk PLHIV)	20
Number of acts per partner (low-risk PLHIV)	40
Transmission probability per act	0.16%
ART efficacy if the user is virally suppressed	100%
ART efficacy if the user is not virally suppressed	50%
HIV prevention coverage when simulated (high-risk only)	50%
HIV prevention efficacy when simulated	90%

Achieving 95-95-95 may not be enough to end AIDS epidemic in South Africa

Dobromir Dimitrov¹, James R. Moore¹, Deborah J. Donnell¹, Marie-Claude Boily² ¹Fred Hutchinson Cancer Research Center, ²Imperial College London

Our model suggests 25% higher HIV A incidence when high-risk PLHIV remain (%) 1.2 uncovered by the HIV treatment cascade HIV incid Achieving 95-95-95 UNAIDS target in South Africa by 2030 will result in 86% overall viral suppression (VS). Estimated reduction in the HIV incidence (64%-89%) compared to 2015 levels strongly depends on the ART and VS (%) coverage achieved among high-risk PLHIV It is unlikely to end the AIDS epidemic if the reduction in HIV incidence does not result in significant HIV prevalence reduction Scale-up of HIV prevention among high-risk people will help bridging the gap to AIDS (%) elimination -1.2

SIMULATED SCENARIOS

- **Two baseline scenarios** simulated the treatment cascade in 2015 with diagnosed, on treatment or virally suppressed PLHIV being either:
- ii. predominately chosen from low-risk group (grey/light-shaded)
- Three scenarios of treatment cascade expansion are simulated with
- proportionally distributed between risk groups (proportional);
- **n**ewly diagnosed, treated and virally suppressed PLHIV being either: ii. predominately recruited from the high-risk group (optimistic); iii. predominately recruited from the low-risk group (pessimistic).
- Three intervention scenarios of reaching UNAIDS targets in 2030 are designed using HIV prevalence projections from published studies³: **HIV prevalence** remains **stable at 17%**, no HIV prevention (**Panel A)**; ii. HIV prevalence decreases to 10%, no HIV prevention (Panel B); iii. HIV prevalence decreases to 10% + extra HIV prevention (Panel C).

REFERENCES

[1] aidsinfo unaids org [2] Mid-year population estimates, Department of Statistics South Africa, 2019 [3] Eaton et. al, Lancet Global Health, 2(1), e23-e34, 2014

The HIV Prevention Trials Network is funded by the National Institute of Allergy and Infectious Diseases (UM1AI068613, UM1AI068617), with co-funding from the National Institute of Mental Health, and the National Institute of Allergy and Infectious Diseases (UM1AI068617), with co-funding from the National Institute of Mental Health, and the National Institute of Mental Health (National Institute of Mental Health), with co-funding from the National Institute of Mental Health (National Institute of Mental Health), with co-funding from the National Institute of Mental Health (National Institute of Mental Health), with co-funding from the National Institute of Mental Health (National Institute of Mental Health) (National Institute of Mental Health), with co-funding from the National Institute of Mental Health (National Institute of Mental Health), with co-funding from the National Institute of Mental Health (National Institute of Mental Health) (National Institute of Menta U.S. National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

proportionally distributed between risk groups (black/dark-shaded)

CONCLUSIONS



London

Imperial College





FRED HUTCH CURES START HERE®



Reaching UNAIDS targets will not necessarily be sufficient to end the HIV epidemic in South Africa especially if the reduction in HIV incidence do not results in HIV prevalence reduction (e.g. if increased PLHIV longevity is not rapidly counterbalanced).

Our analysis suggests that without HIV prevention scale-up practically all high-risk PLHIV may need to be virally suppressed for HIV incidence to fall below **AIDS elimination threshold**. • More detailed, dynamic modeling studies are needed to understand the contribution of different high-risk groups and identify optimal combinations between treatment and prevention with a chance to end the HIV epidemic in South Africa.